Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Encorafenib/Binimetinib With or Without Nivolumab for Patients With Metastatic BRAF V600 Mutant Thyroid Cancer

NCT04061980 is registered in ClinicalTrials.gov with Providence Health & Services as lead sponsor.

NCT NCT04061980
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04061980 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Encorafenib/Binimetinib With or Without Nivolumab for Patients With Metastatic BRAF V600 Mutant Thyroid Cancer
Lead sponsor
Providence Health & Services
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 30, 2020
Completion date
December 30, 2028
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

braf np_004324.2:p.v600m, braf v600e mutation present, metastatic thyroid gland carcinoma, refractory thyroid gland carcinoma, stage iv differentiated thyroid gland carcinoma ajcc v8, stage iva differentiated thyroid gland carcinoma ajcc v8, stage ivb differentiated thyroid gland carcinoma ajcc v8